Page contents Key factsDecisionKey facts Active Substance Pexastimogene devacirepvec Therapeutic area Oncology Decision number P/0201/2017 PIP number EMEA-002124-PIP01-17 Pharmaceutical form(s) Suspension for injection Condition(s) / indication(s) Treatment of hepatocellular carcinoma Route(s) of administration Intratumoral use Contact for public enquiries Transgene S.A.FranceTel. +33 388279155E-mail: clinical.trials@transgene.fr Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 14/07/2017DecisionP/0201/2017: EMA decision of 14 July 2017 on the granting of a product-specific waiver for pexastimogene devacirepvec (EMEA-002124-PIP01-17)AdoptedReference Number: EMA/444489/2017 English (EN) (63.82 KB - PDF)First published: 28/09/2017Last updated: 28/09/2017ViewShare this page